enGene (NASDAQ:ENGN) Now Covered by Analysts at WBB Securities

WBB Securities began coverage on shares of enGene (NASDAQ:ENGN) in a research note released on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $21.50 price objective on the stock.

A number of other research analysts also recently commented on ENGN. Raymond James Financial reiterated a “strong-buy” rating and set a $27.00 target price on shares of enGene in a research report on Monday, March 9th. Citigroup reiterated a “market outperform” rating on shares of enGene in a research report on Monday, January 5th. Oppenheimer lowered their target price on enGene from $33.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. Wall Street Zen upgraded enGene from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of enGene in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $22.69.

enGene Trading Up 3.2%

ENGN stock opened at $7.43 on Monday. enGene has a 1-year low of $2.65 and a 1-year high of $12.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 11.75. The company has a market capitalization of $497.74 million, a price-to-earnings ratio of -3.30 and a beta of -0.06. The business has a 50 day simple moving average of $8.34 and a two-hundred day simple moving average of $8.35.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.11. Research analysts anticipate that enGene will post -1.56 EPS for the current fiscal year.

Institutional Trading of enGene

A number of institutional investors have recently bought and sold shares of the stock. PFS Partners LLC lifted its position in enGene by 22.2% in the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after buying an additional 2,000 shares during the last quarter. Millennium Management LLC lifted its position in enGene by 57.3% in the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares during the last quarter. Raymond James Financial Inc. increased its stake in enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares during the period. Cresset Asset Management LLC purchased a new stake in enGene in the second quarter worth $36,000. Finally, Paloma Partners Management Co purchased a new stake in enGene in the second quarter worth $38,000. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.